Lipid Disorders
Conference Coverage
AHA: New emphasis on percent LDL reduction on-treatment
Key clinical point: An individual’s percent reduction in LDL cholesterol achieved on statin therapy is a clinically important measurement. Major...
News
AHA: HDL – the waters grow muddier
Doubt has emerged about the validity of HDL cholesterol as a straightforward cardiovascular risk factor.
Conference Coverage
Novel botanical drug reduces hepatic fat content
Twelve weeks of treatment with a novel botanical drug extracted from Magnolia officinalis safely and significantly reduced hepatic fat content in...
News
AHA: SPRINT’s results upend hypertension targets
Key clinical point: The first full report of results from the SPRINT trial of hypertension treatment targets generated lots of opinions on their...
Conference Coverage
VIDEO: SPRINT resets many patients’ hypertension treatment target
Results from the SPRINT trial provide evidence for a lower blood pressure target for many patients but don’t address who is hypertensive.
Conference Coverage
Researchers highlight gaps in diabetes screening in patients on antipsychotics
Key clinical point: Most patients with severe mental illness who are taking antipsychotics are not being screened for diabetes. Major finding: Out...
Conference Coverage
Even subclinical hypothyroidism ups risk for metabolic syndrome
Conference Coverage
EADV: Hidradenitis suppurativa carries high cardiovascular risk
Key clinical point: Be vigilant in screening for modifiable cardiovascular risk factors in patients with hidradenitis suppurativa. Major finding:...
Conference Coverage
EASD: Evolocumab shows ‘promising efficacy’ in type 2 diabetes
Evolocumab, used in addition to the standard of care, lowered LDL-C and improved other lipid parameters in people with type 2 diabetes just as...